Brought to you by 
Gilead licenses Japan Tobacco's HIV integrase inhibitor
19 May 2015
Executive Summary
Gilead Sciences (drugs for infectious diseases) has licensed exclusive worldwide rights outside of Japan to develop and sell Japan Tobacco's HIV integrase inhibitor JTK-303.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com